{"id":"W4387962267","doi":"10.1200/op.2023.19.11_suppl.332","title":"Patient-reported outcomes (PROs) in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab (D) plus carboplatin/paclitaxel (CP) compared with CP in the ENGOT-EN6/GOG3031/RUBY trial.","year":2023,"lang":"en","type":"article","venue":"JCO Oncology Practice","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Placebo; Endometrial cancer; Internal medicine; Population; Carboplatin; Quality of life (healthcare); Urology; Progression-free survival; Paclitaxel; Clinical endpoint; Gastroenterology; Randomized controlled trial; Oncology; Cancer; Chemotherapy; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002385598,0.0005701877,0.0009499612,0.0002307684,0.0001774581,0.0004842978,0.0003038467,0.0005953971,0.001572392],"category_scores_gemma":[0.001671303,0.0001943734,0.001540755,0.0003581383,0.0002887083,0.0003400939,0.0003627112,0.001089496,0.0001896366],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003203432,"about_ca_system_score_gemma":0.0003572748,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004539404,"about_ca_topic_score_gemma":0.0009344408,"domain_scores_codex":[0.9991643,0.0005913879,0.00004413986,0.00007869861,0.00005885907,0.00006258617],"domain_scores_gemma":[0.9991482,0.0002420037,0.0003711135,0.00003512112,0.00003607593,0.0001674406],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8665657,0.002512531,0.05369191,0.001640434,0.005656551,0.00009946751,0.0001225578,0.002242035,0.002982155,0.000111941,0.001452533,0.06292217],"study_design_scores_gemma":[0.2897724,0.3292969,0.3591533,0.0003131752,0.01002803,0.0004659746,0.0002031042,0.004609642,0.002081612,0.0004692117,0.003543135,0.00006355184],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923407,0.005543851,0.0001659077,0.0001912349,0.00004449357,0.0002395678,0.0008371149,0.00001509717,0.0006220924],"genre_scores_gemma":[0.9975799,0.0008367876,0.0002123408,0.0001597162,0.00004272844,0.0003327661,0.0005986943,0.000002678339,0.0002345671],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002385598,"threshold_uncertainty_score":0.0126164,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05341484935085666,"score_gpt":0.3653009875459587,"score_spread":0.3118861381951021,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}